E484K, la mutation qui pose question pour les vaccins

Référence 4 de la bibliographie de l’article :

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7)
▻https://www.aekstmk.or.at/images/content/pdfs/covid19/Impf/Lancet%202021%20AZD1222%20efficacy%20against%20B1_1_7_%20variant.pdf

Malgré une activité neutralisante divisée par 9 vis-à-vis du variant « britannique », le vaccin Oxford/AstraZeneca est aussi efficace contre ce dernier qu’il l’est vis-à-vis du virus « chinois ».

Virus neutralisation activity by vaccine- induced antibodies was 9-fold lower against the B.1.1.7 variant than against a canonical non- B.1.1.7 lineage.

Vaccine efficacy against symptomatic NAAT positive infection was similar for B.1.1.7 and non-B1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). [...]

Interpretation
Efficacy of ChAdOx1 nCoV-19 against the B.1.1.7 variant of SARS-CoV-2 is similar to the efficacy of the vaccine against other lineages. Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease.

De l’article de Science :

It has been posited that SARS-CoV-2 may continue to accumulate mutations that evade immune responses (10). But as previously explored for other viruses, such as HIV, immune evasion often comes at a biological fitness cost to the virus , tending to impose an upper limit to the number of mutations that can be afforded when faced with a broad, neutralizing antibody repertoire (11).

Covid-19 : E484K, la mutation qui pose question pour les vaccins
▻https://seenthis.net/messages/906365